Bespoke Gene Therapy Consortium award
On May 16, 2023, the Bespoke Gene Therapy Consortium (BGTC) announced our gene therapy project partners Children’s Hospital of Philadelphia (CHOP) as award recipients. The BGTC is a public-private partnership funded by the National Institutes of Health (NIH).
This award will fund the manufacturing of the AAV9 gene therapy and Phase I/II clinical trials and keeps the United MSD Foundation on track with its goal of gene therapy as a potential treatment option.
Links To Helpful Information
Accelerating Medicines Partnership® (AMP®) program’s Bespoke Gene Therapy Consortium overview
Children’s Hospital of Philadelphia Bespoke selection press release
FNIH Bespoke award press release
FNIH press release re: publication of Regulatory Playbook to Advance AAV Gene Therapies for Rare Diseases (Feb 6, 2024)
FNIH Bespoke Gene Therapy Consortium (BGTC) Regulatory Playbook Version 1.0
Foundation for the National Institutes of Health (FNIH) (BGTC page)
COMMONLY ASKED QUESTIONS
What will the Bespoke award fund?
The Bespoke award will fund the manufacturing of the AAV9 gene therapy and Phase I/II clinical trials.
Who received the award?
The Children’s Hospital of Philadelphia (CHOP) received the award, with Dr. Rebecca Ahrens-Nicklas and Dr. Laura Adang being the co-Primary Investigators.
What is the United MSD Foundation’s role in the project?
The United MSD Foundation has been a driving force behind the foundational steps to clinical trials, including advocating for research on MSD, establishing a Biobank, and funding a Natural History Study, and a toxicology study. For this project, the Foundation has pledged $300,000 toward patient travel for the clinical trials.
At the end of the award, will gene therapy be available to all MSD children?
We do not have an answer at this time. At the end of the clinical trial, everything will have to go through regulatory approval or the FDA.
When will the clinical trial start?
We do not have an answer at this time. Please check back periodically for more information.
How long will enrollment be open for?
We do not have an answer at this time. Please check back periodically for more information.
If accepted, how long is the estimated trial timeline?
Clinical trials will run for six years from the start of the trial.
Who will be eligible for the clinical trial?
We do not yet know the eligibility criteria for the clinical trial. It will be determined once the protocol is finalized as a part of the FDA application.
Are there any exclusion criteria?
We do not yet know the exclusion criteria for the clinical trial. It will be determined once the protocol is finalized as a part of the FDA application.
How do I express interest in enrolling my child in the clinical trial?
When the clinical trial is recruiting, it will be posted on ClinicalTrials.Gov. The United MSD Foundation will also distribute information at that time. If you are not already engaged in the Natural History Study, please consider participating.
Will the clinical trial be open to U.S. and international families?
We do not have an answer at this time. Please check back periodically for more information.
Will there be travel assistance for participating in the trial?
Yes. As a part of the Bespoke Grant proposal, the United MSD Foundation pledged $300,000 toward patient travel for the clinical trial.
Will this reverse the progression of MSD?
There is no scientific evidence that AAV9 gene therapy will reverse the progression of MSD.
With the Bespoke award funding the clinical trial, does that mean the Foundation doesn’t need to fundraise anymore?
No, there are still research and family support funding needs. The Bespoke award solidifies funding for the next steps of the AAV9 gene therapy development.
Let’s Connect
Connect with MSD families and get valuable information from medical researchers and doctors.